You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePerphenazine
Accession NumberDB00850  (APRD00429)
TypeSmall Molecule
GroupsApproved
DescriptionAn antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. [PubChem]
Structure
Thumb
Synonyms
2-(4-[3-(2-chloro-10H-Phenothiazin-10-yl)propyl]-1-piperazinyl)ethanol
2-chloro-10-(3-(4-(2-Hydroxyethyl)piperazin-1-yl)propyl)phenothiazine
4-[3-(2-chloro-10H-Phenothiazin-10-yl)propyl]-1-piperazineethanol
4-[3-(2-Chlorophenothiazin-10-yl)propyl]-1-piperazineethanol
Chlorpiprazine
Etaperazin
Etaperazine
Ethaperazine
gamma-(4-(beta-Hydroxyethyl)piperazin-1-yl)propyl-2-chlorophenothiazine
Perfenazina
Perfenazine
Perphenazin
Perphénazine
Perphenazinum
Trilafon
External Identifiers
  • SC 7105
  • Sch 3940
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PerphenazineTablet16 mgOralAa Pharma Inc1976-12-31Not applicableCanada
PerphenazineTablet8 mgOralAa Pharma Inc1976-12-31Not applicableCanada
PerphenazineTablet4 mgOralAa Pharma Inc1976-12-31Not applicableCanada
PerphenazineTablet2 mgOralAa Pharma Inc1976-12-31Not applicableCanada
Perphenazine 16 TabTablet16 mgOralPro Doc Limitee1982-12-312010-07-13Canada
Perphenazine 2 Tab 2mgTablet2 mgOralPro Doc Limitee1982-12-312010-07-13Canada
Perphenazine 8 Tab 8mgTablet8 mgOralPro Doc Limitee1982-12-312010-07-13Canada
Perphenazine Tab 2mgTablet2 mgOralD.C. Labs Limited1979-12-312003-07-11Canada
Perphenazine Tab 4mgTablet4 mgOralPro Doc Limitee1982-12-312010-07-13Canada
Perphenazine Tab 4mgTablet4 mgOralD.C. Labs Limited1979-12-312003-07-11Canada
Phenazine 16 TabTablet16 mgOralIcn Canada Ltd.1974-12-311998-08-13Canada
Phenazine 2 TabTablet2 mgOralIcn Canada Ltd.1973-12-311998-08-13Canada
Phenazine 4 TabTablet4 mgOralIcn Canada Ltd.1973-12-311998-08-13Canada
Phenazine 8 TabTablet8 mgOralIcn Canada Ltd.1974-12-311998-08-13Canada
PMS Perphenazine Concentrate Liq 3.2mg/mlLiquid3.2 mgOralPharmascience Inc1988-12-31Not applicableCanada
PMS Perphenazine Tab 16mgTablet16 mgOralPharmascience Inc1987-12-31Not applicableCanada
PMS Perphenazine Tab 2mgTablet2 mgOralPharmascience Inc1987-12-31Not applicableCanada
PMS Perphenazine Tab 4mgTablet4 mgOralPharmascience Inc1987-12-31Not applicableCanada
PMS Perphenazine Tab 8mgTablet8 mgOralPharmascience Inc1987-12-31Not applicableCanada
Trilafon Conc 16mg/5mlLiquid16 mgOralSchering Plough Canada Inc1958-12-311997-12-01Canada
Trilafon Inj 5mg/mlSolution5 mgIntramuscular; IntravenousSchering Plough Canada Inc1958-12-312006-08-01Canada
Trilafon Syr 2mg/5mlSyrup2 mgOralSchering Plough Canada Inc1958-12-311996-11-08Canada
Trilafon Tab 2mgTablet2 mgOralSchering Plough Canada Inc1957-12-312000-07-11Canada
Trilafon Tab 4mgTablet4 mgOralSchering Plough Canada Inc1957-12-311998-11-17Canada
Trilafon Tab 8mgTablet8 mgOralSchering Plough Canada Inc1957-12-311996-09-10Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PerphenazineTablet, film coated2 mg/1OralSandoz Inc1988-12-08Not applicableUs
PerphenazineTablet, film coated8 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
PerphenazineTablet, film coated16 mg/1OralREMEDYREPACK INC.2008-11-03Not applicableUs
PerphenazineTablet, film coated2 mg/1OralQualitest Pharmaceuticals1998-12-31Not applicableUs
PerphenazineTablet, film coated8 mg/1OralREMEDYREPACK INC.2013-03-202016-11-02Us
PerphenazineTablet, film coated2 mg/1OralREMEDYREPACK INC.2015-10-19Not applicableUs
PerphenazineTablet, film coated16 mg/1OralClinical Solutions Wholesale1998-12-31Not applicableUs
PerphenazineTablet, film coated4 mg/1OralRebel Distributors Corp2010-04-07Not applicableUs
PerphenazineTablet, film coated4 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
PerphenazineTablet, film coated2 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1988-12-08Not applicableUs
PerphenazineTablet, sugar coated2 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
PerphenazineTablet, film coated8 mg/1OralAmerican Health Packaging2012-05-01Not applicableUs
PerphenazineTablet, film coated4 mg/1OralSandoz Inc1988-12-08Not applicableUs
PerphenazineTablet, sugar coated8 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
PerphenazineTablet, film coated2 mg/1OralClinical Solutions Wholesale1998-12-31Not applicableUs
PerphenazineTablet, film coated4 mg/1OralQualitest Pharmaceuticals1998-12-31Not applicableUs
PerphenazineTablet, film coated4 mg/1OralREMEDYREPACK INC.2012-09-26Not applicableUs
PerphenazineTablet, film coated4 mg/1OralContract Pharmacy Services Pa2010-04-07Not applicableUs
PerphenazineTablet, film coated8 mg/1OralRebel Distributors Corp2010-04-07Not applicableUs
PerphenazineTablet, film coated2 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
PerphenazineTablet, film coated2 mg/1OralREMEDYREPACK INC.2015-09-30Not applicableUs
PerphenazineTablet, film coated4 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1988-12-08Not applicableUs
PerphenazineTablet, film coated2 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
PerphenazineTablet, film coated2 mg/1OralAmerican Health Packaging2014-09-17Not applicableUs
PerphenazineTablet, film coated8 mg/1OralSandoz Inc1988-12-08Not applicableUs
PerphenazineTablet, film coated16 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
PerphenazineTablet, film coated4 mg/1OralClinical Solutions Wholesale1998-12-31Not applicableUs
PerphenazineTablet, film coated8 mg/1OralQualitest Pharmaceuticals1998-12-31Not applicableUs
PerphenazineTablet, film coated8 mg/1OralREMEDYREPACK INC.2013-11-12Not applicableUs
PerphenazineTablet, film coated8 mg/1OralContract Pharmacy Services Pa2010-04-07Not applicableUs
PerphenazineTablet8 mg/1OralREMEDYREPACK INC.2011-10-192016-03-12Us
PerphenazineTablet, film coated2 mg/1OralCardinal Health1988-12-08Not applicableUs
PerphenazineTablet, film coated2 mg/1OralREMEDYREPACK INC.2008-10-29Not applicableUs
PerphenazineTablet, film coated8 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1988-12-08Not applicableUs
PerphenazineTablet, film coated4 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
PerphenazineTablet, film coated16 mg/1OralAmerican Health Packaging2014-10-09Not applicableUs
PerphenazineTablet, film coated16 mg/1OralSandoz Inc1988-12-08Not applicableUs
PerphenazineTablet, film coated16 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
PerphenazineTablet, film coated8 mg/1OralClinical Solutions Wholesale1998-12-31Not applicableUs
PerphenazineTablet, film coated16 mg/1OralQualitest Pharmaceuticals1998-12-31Not applicableUs
PerphenazineTablet, sugar coated8 mg/1OralH.J. Harkins Company, Inc.1998-12-31Not applicableUs
PerphenazineTablet, film coated4 mg/1OralAmerican Health Packaging2012-04-04Not applicableUs
PerphenazineTablet, film coated4 mg/1OralREMEDYREPACK INC.2013-03-262016-11-02Us
PerphenazineTablet, film coated4 mg/1OralREMEDYREPACK INC.2015-09-17Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DecentanMerck
EmesinalNot Available
FentazinMercury
PerphenanTaro
PZCTanabe Mitsubishi Pharma
TrilafonSchering-Plough
TrilifanNot Available
Brand mixtures
NameLabellerIngredients
Apo Peram Tab 2-25Apotex Inc
Apo Peram Tab 3-15Apotex Inc
Elavil Plus TabTriton Pharma Inc
Etrafon 2 10Schering Plough Canada Inc
Etrafon A TabSchering Plough Canada Inc
Etrafon D TabSchering Plough Canada Inc
Etrafon F TabSchering Plough Canada Inc
Perphenazine and Amitriptyline HydrochlorideREMEDYREPACK INC.
PMS-levazine 2/25 TabPharmascience Inc
PMS-levazine 3/15 TabPharmascience Inc
PMS-levazine 4/25 TabPharmascience Inc
Proavil TabPro Doc Limitee
Triavil TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
Salts
Name/CASStructureProperties
Perphenazine enanthate
ThumbNot applicableDBSALT000936
Perphenazine heptanoate
ThumbNot applicableDBSALT000937
Categories
UNIIFTA7XXY4EZ
CAS number58-39-9
WeightAverage: 403.969
Monoisotopic: 403.148510866
Chemical FormulaC21H26ClN3OS
InChI KeyRGCVKNLCSQQDEP-UHFFFAOYSA-N
InChI
InChI=1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2
IUPAC Name
2-{4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]piperazin-1-yl}ethan-1-ol
SMILES
OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
Pharmacology
IndicationFor use in the management of the manifestations of psychotic disorders and for the control of severe nausea and vomiting in adults.
Structured Indications
PharmacodynamicsPerphenazine is a piperazinyl phenothiazine, acts on the central nervous system, and has a greater behavioral potency than other phenothiazine derivatives whose side chains do not contain a piperazine moiety. It is a member of a class of drugs called phenothiazines, which are dopamine D1/D2 receptor antagonists. Perphenazine is 10 to 15 times as potent as chlorpromazine; that means perphenazine is a highly potent antipsychotic. In equivalent doses it has approximately the same frequency and severity of early and late extrapypramidal side-effects compared to Haloperidol.
Mechanism of actionBinds to the dopamine D1 and dopamine D2 receptors and inhibits their activity. The mechanism of the anti-emetic effect is due predominantly to blockage of the dopamine D2 neurotransmitter receptors in the chemoreceptor trigger zone and vomiting centre. Perphenazine also binds the alpha andrenergic receptor. This receptor's action is mediated by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
TargetKindPharmacological actionActionsOrganismUniProt ID
D(2) dopamine receptorProteinyes
antagonist
HumanP14416 details
D(1A) dopamine receptorProteinyes
antagonist
HumanP21728 details
CalmodulinProteinunknown
inhibitor
HumanP62158 details
Related Articles
AbsorptionAbsolute bioavailability is 40% following oral administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationPerphenazine is extensively metabolized in the liver to a number of metabolites by sulfoxidation, hydroxylation, dealkylation, and glucuronidation.
Half life8-12 hours, but ranges up to 20 hours.
ClearanceNot Available
ToxicitySymptoms of overdose include stupor or coma, and children may have convulsive seizures. Signs of arousal may not occur for 48 hours. Oral LD50=318 mg/kg (rat); IPR LD50=64 mg/kg (mouse)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Perphenazine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetaminePerphenazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetaminePerphenazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetaminePerphenazine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetaminePerphenazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Perphenazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Perphenazine is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Perphenazine can be increased when it is combined with Abiraterone.Approved
AcebutololPerphenazine may increase the hypotensive activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Aceprometazine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Perphenazine is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Perphenazine.Approved, Illicit
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Perphenazine.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Perphenazine is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Perphenazine.Approved, Illicit, Investigational
AlprenololPerphenazine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmantadineThe therapeutic efficacy of Perphenazine can be decreased when used in combination with Amantadine.Approved
AmiodaroneThe metabolism of Perphenazine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Perphenazine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Perphenazine is combined with Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Perphenazine can be increased when it is combined with Amodiaquine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Perphenazine is combined with Amperozide.Experimental
AmphetaminePerphenazine may decrease the stimulatory activities of Amphetamine.Approved, Illicit
Aop200704Perphenazine may increase the hypotensive activities of Aop200704.Investigational
ApomorphineThe therapeutic efficacy of Perphenazine can be decreased when used in combination with Apomorphine.Approved, Investigational
AprepitantThe serum concentration of Perphenazine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Perphenazine.Approved, Investigational
ArmodafinilThe metabolism of Perphenazine can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololPerphenazine may increase the hypotensive activities of Arotinolol.Approved
ArtemetherThe serum concentration of Perphenazine can be increased when it is combined with Artemether.Approved
ArtemisininThe serum concentration of Perphenazine can be increased when it is combined with Artemisinin.Investigational
ArtesunateThe serum concentration of Perphenazine can be increased when it is combined with Artesunate.Approved
ArticaineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Asenapine.Approved
AtazanavirThe metabolism of Perphenazine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololPerphenazine may increase the hypotensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Perphenazine can be decreased when combined with Atomoxetine.Approved
AtovaquoneThe serum concentration of Perphenazine can be increased when it is combined with Atovaquone.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Azaperone.Vet Approved
AzelastinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Azelastine.Approved
AzithromycinThe metabolism of Perphenazine can be decreased when combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Perphenazine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Perphenazine is combined with Barbital.Illicit
BefunololPerphenazine may increase the hypotensive activities of Befunolol.Experimental
BenperidolThe risk or severity of adverse effects can be increased when Perphenazine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Benzocaine.Approved
BenzphetaminePerphenazine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Perphenazine is combined with Benzyl alcohol.Approved
BetaxololThe metabolism of Perphenazine can be decreased when combined with Betaxolol.Approved
Betulinic AcidThe serum concentration of Perphenazine can be increased when it is combined with Betulinic Acid.Investigational
BevantololPerphenazine may increase the hypotensive activities of Bevantolol.Approved
BexaroteneThe serum concentration of Perphenazine can be decreased when it is combined with Bexarotene.Approved, Investigational
BezitramidePerphenazine may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BisoprololPerphenazine may increase the hypotensive activities of Bisoprolol.Approved
BoceprevirThe metabolism of Perphenazine can be decreased when combined with Boceprevir.Approved
BopindololPerphenazine may increase the hypotensive activities of Bopindolol.Approved
BortezomibThe metabolism of Perphenazine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Perphenazine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Perphenazine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Bromazepam.Approved, Illicit
BromocriptineThe therapeutic efficacy of Perphenazine can be decreased when used in combination with Bromocriptine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Brotizolam.Approved, Withdrawn
BucindololPerphenazine may increase the hypotensive activities of Bucindolol.Investigational
BufuralolPerphenazine may increase the hypotensive activities of Bufuralol.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Perphenazine.Approved, Investigational
BupranololPerphenazine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Perphenazine can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Perphenazine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Perphenazine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Perphenazine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Perphenazine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Perphenazine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Perphenazine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Perphenazine.Approved
CaffeineThe metabolism of Perphenazine can be decreased when combined with Caffeine.Approved
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CapecitabineThe metabolism of Perphenazine can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Perphenazine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Perphenazine is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Perphenazine is combined with Carisoprodol.Approved
CarteololPerphenazine may increase the hypotensive activities of Carteolol.Approved
CarvedilolPerphenazine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Perphenazine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololPerphenazine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Perphenazine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Perphenazine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Perphenazine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Perphenazine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Chloroprocaine.Approved
ChloroquineThe serum concentration of Perphenazine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Chlorphenamine.Approved
ChlorphenterminePerphenazine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe metabolism of Perphenazine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Perphenazine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Perphenazine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Perphenazine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Perphenazine.Approved, Vet Approved
CitalopramThe metabolism of Perphenazine can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Perphenazine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Perphenazine can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Perphenazine is combined with Clidinium.Approved
ClobazamThe metabolism of Perphenazine can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Perphenazine is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Perphenazine can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Clonidine.Approved
ClopidogrelThe metabolism of Perphenazine can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Perphenazine.Approved, Illicit
ClotrimazoleThe metabolism of Perphenazine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Perphenazine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Perphenazine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Perphenazine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Perphenazine.Approved, Illicit
ConivaptanThe serum concentration of Perphenazine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Perphenazine can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Cyclobenzaprine.Approved
CyclosporineThe metabolism of Perphenazine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Perphenazine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Perphenazine can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Perphenazine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dapoxetine.Investigational
DapsoneThe serum concentration of Perphenazine can be increased when it is combined with Dapsone.Approved, Investigational
DarifenacinThe metabolism of Perphenazine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Perphenazine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Perphenazine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Perphenazine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Perphenazine can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Perphenazine is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Desflurane.Approved
DesipramineThe metabolism of Perphenazine can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Perphenazine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Perphenazine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Perphenazine.Approved, Vet Approved
DextroamphetaminePerphenazine may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Perphenazine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Perphenazine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Perphenazine.Approved, Illicit, Vet Approved
DiethylpropionPerphenazine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Perphenazine is combined with Difenoxin.Approved, Illicit
DihydroartemisininThe serum concentration of Perphenazine can be increased when it is combined with Dihydroartemisinin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Perphenazine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Perphenazine can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Perphenazine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Perphenazine is combined with Diphenoxylate.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Perphenazine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Perphenazine is combined with Doxepin.Approved
DoxorubicinThe metabolism of Perphenazine can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe serum concentration of Perphenazine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Perphenazine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.Approved, Illicit
DronedaroneThe metabolism of Perphenazine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Perphenazine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe metabolism of Perphenazine can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Perphenazine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Perphenazine is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Perphenazine can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Perphenazine.Approved, Investigational
EliglustatThe metabolism of Perphenazine can be decreased when combined with Eliglustat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Perphenazine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Perphenazine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Perphenazine can be decreased when it is combined with Enzalutamide.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Perphenazine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Perphenazine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Perphenazine.Approved
ErythromycinThe metabolism of Perphenazine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Perphenazine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Perphenazine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololPerphenazine may increase the hypotensive activities of Esmolol.Approved
EsomeprazoleThe metabolism of Perphenazine can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Perphenazine.Approved
EthanolPerphenazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Perphenazine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Perphenazine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Perphenazine can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Perphenazine is combined with Felbamate.Approved
FelodipineThe metabolism of Perphenazine can be decreased when combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fenfluramine.Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Perphenazine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Perphenazine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Perphenazine is combined with Flibanserin.Approved
FloxuridineThe metabolism of Perphenazine can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Perphenazine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Flunitrazepam.Approved, Illicit
FluorouracilThe metabolism of Perphenazine can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Perphenazine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Perphenazine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Perphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Perphenazine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Perphenazine can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Perphenazine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Perphenazine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Perphenazine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Perphenazine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Perphenazine.Approved, Investigational
Fusidic AcidThe serum concentration of Perphenazine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Perphenazine is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Perphenazine is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Perphenazine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GemfibrozilThe metabolism of Perphenazine can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Perphenazine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Perphenazine is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Perphenazine.Approved, Illicit, Withdrawn
HalofantrineThe serum concentration of Perphenazine can be increased when it is combined with Halofantrine.Approved
HaloperidolThe metabolism of Perphenazine can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Perphenazine is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Perphenazine is combined with Hexobarbital.Approved
HydrocodonePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Perphenazine.Approved, Illicit
Hydroxyamphetamine hydrobromidePerphenazine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxychloroquineThe serum concentration of Perphenazine can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.Approved
IdelalisibThe serum concentration of Perphenazine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Iloperidone.Approved
ImatinibThe metabolism of Perphenazine can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Perphenazine can be decreased when combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Indalpine.Investigational, Withdrawn
IndenololPerphenazine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Perphenazine can be decreased when combined with Indinavir.Approved
IrbesartanThe metabolism of Perphenazine can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Perphenazine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Perphenazine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Perphenazine.Approved, Vet Approved
IsoniazidThe metabolism of Perphenazine can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Perphenazine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Perphenazine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Perphenazine can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Perphenazine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolPerphenazine may increase the hypotensive activities of Labetalol.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Lamotrigine.Approved, Investigational
LapatinibThe metabolism of Perphenazine can be decreased when combined with Lapatinib.Approved, Investigational
LeflunomideThe metabolism of Perphenazine can be decreased when combined with Leflunomide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Levetiracetam.Approved, Investigational
LevobunololPerphenazine may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Perphenazine can be decreased when used in combination with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Perphenazine is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Perphenazine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Perphenazine is combined with Levorphanol.Approved
LidocaineThe metabolism of Perphenazine can be decreased when combined with Lidocaine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Perphenazine.Approved, Investigational
LisdexamfetaminePerphenazine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Perphenazine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Perphenazine is combined with Lofentanil.Illicit
LopinavirThe metabolism of Perphenazine can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Perphenazine.Approved
LorcaserinThe metabolism of Perphenazine can be decreased when combined with Lorcaserin.Approved
LosartanThe metabolism of Perphenazine can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Perphenazine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Perphenazine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Perphenazine is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Perphenazine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Perphenazine can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Perphenazine can be increased when it is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Lurasidone.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Medetomidine.Vet Approved
MefloquineThe serum concentration of Perphenazine can be increased when it is combined with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Perphenazine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Melperone.Approved
MephedronePerphenazine may decrease the stimulatory activities of Mephedrone.Investigational
MephenterminePerphenazine may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Perphenazine.Approved, Illicit
MequitazinePerphenazine may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Metaxalone.Approved
MethadoneThe metabolism of Perphenazine can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methadyl Acetate.Approved, Illicit
MethamphetaminePerphenazine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Perphenazine.Approved
MethotrimeprazinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methsuximide.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Perphenazine.Approved
MetipranololPerphenazine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Perphenazine.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Perphenazine.Approved, Investigational
MetyrosinePerphenazine may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Perphenazine can be decreased when combined with Mexiletine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Perphenazine.Approved, Illicit
MifepristoneThe serum concentration of Perphenazine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Perphenazine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.Approved, Investigational
MirabegronThe metabolism of Perphenazine can be decreased when combined with Mirabegron.Approved
MirtazapinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Perphenazine can be decreased when it is combined with Mitotane.Approved
MizoribineThe serum concentration of Perphenazine can be increased when it is combined with Mizoribine.Investigational
MMDAPerphenazine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe metabolism of Perphenazine can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Perphenazine can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Perphenazine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.Approved, Investigational
NadololPerphenazine may increase the hypotensive activities of Nadolol.Approved
NafcillinThe serum concentration of Perphenazine can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Perphenazine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Perphenazine.Approved, Investigational
NefazodoneThe metabolism of Perphenazine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Perphenazine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Perphenazine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Perphenazine can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Perphenazine can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Perphenazine can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Perphenazine is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Perphenazine can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Olopatadine.Approved
OmeprazoleThe metabolism of Perphenazine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Perphenazine is combined with Opium.Approved, Illicit
OrphenadrinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Perphenazine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Perphenazine can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Perphenazine.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Perphenazine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Perphenazine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Oxymorphone.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Perphenazine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Paliperidone.Approved
PanobinostatThe serum concentration of Perphenazine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Perphenazine can be decreased when combined with Pantoprazole.Approved
ParaldehydePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe metabolism of Perphenazine can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Perphenazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPerphenazine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Perphenazine.Approved, Vet Approved
PentobarbitalThe metabolism of Perphenazine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perphenazine is combined with Perospirone.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Perphenazine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Perphenazine.Approved
PhenobarbitalThe metabolism of Perphenazine can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Perphenazine is combined with Phenoxyethanol.Approved
PhenterminePerphenazine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe metabolism of Perphenazine can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Perphenazine is combined with Pimozide.Approved
PindololPerphenazine may increase the hypotensive activities of Pindolol.Approved
PioglitazoneThe metabolism of Perphenazine can be decreased when combined with Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Pipotiazine.Approved
PiribedilThe therapeutic efficacy of Perphenazine can be decreased when used in combination with Piribedil.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Perphenazine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Perphenazine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Perphenazine is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Perphenazine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPerphenazine may increase the hypotensive activities of Practolol.Approved
PramipexolePerphenazine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Perphenazine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Perphenazine.Approved
PrimaquineThe serum concentration of Perphenazine can be increased when it is combined with Primaquine.Approved
PrimidoneThe metabolism of Perphenazine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Perphenazine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Perphenazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Perphenazine.Approved, Vet Approved
ProguanilThe serum concentration of Perphenazine can be increased when it is combined with Proguanil.Approved
PromazineThe metabolism of Perphenazine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Perphenazine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Perphenazine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Propoxycaine.Approved
PropranololPerphenazine may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Perphenazine is combined with PSD502.Investigational
PseudoephedrinePerphenazine may decrease the stimulatory activities of Pseudoephedrine.Approved
PyrimethamineThe serum concentration of Perphenazine can be increased when it is combined with Pyrimethamine.Approved, Vet Approved
PyronaridineThe serum concentration of Perphenazine can be increased when it is combined with Pyronaridine.Investigational
QuazepamThe serum concentration of Perphenazine can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Quetiapine.Approved
QuinacrineThe serum concentration of Perphenazine can be increased when it is combined with Quinacrine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Perphenazine.Approved
QuinidineThe metabolism of Perphenazine can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Perphenazine can be increased when it is combined with Quinine.Approved
RabeprazoleThe metabolism of Perphenazine can be decreased when combined with Rabeprazole.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Perphenazine is combined with Raclopride.Investigational
RadicicolThe serum concentration of Perphenazine can be increased when it is combined with Radicicol.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Perphenazine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Perphenazine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Perphenazine is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Perphenazine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Perphenazine.Approved
RifabutinThe metabolism of Perphenazine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Perphenazine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Perphenazine can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Perphenazine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ritanserin.Investigational
RitobegronPerphenazine may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe metabolism of Perphenazine can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Perphenazine.Approved
RolapitantThe metabolism of Perphenazine can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Romifidine.Vet Approved
RopinirolePerphenazine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Perphenazine.Approved
RosiglitazoneThe metabolism of Perphenazine can be decreased when combined with Rosiglitazone.Approved, Investigational
RotigotinePerphenazine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Perphenazine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Perphenazine is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Perphenazine is combined with Sage 547.Investigational
SaquinavirThe metabolism of Perphenazine can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Perphenazine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Perphenazine.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Perphenazine is combined with Sertindole.Approved, Withdrawn
SertralineThe metabolism of Perphenazine can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Perphenazine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Perphenazine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Perphenazine can be increased when it is combined with Simeprevir.Approved
SinefunginThe serum concentration of Perphenazine can be increased when it is combined with Sinefungin.Experimental
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.Approved
SorafenibThe metabolism of Perphenazine can be decreased when combined with Sorafenib.Approved, Investigational
SotalolPerphenazine may increase the hypotensive activities of Sotalol.Approved
St. John's WortThe serum concentration of Perphenazine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Perphenazine can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Perphenazine.Approved, Investigational
SulfadiazineThe metabolism of Perphenazine can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfadoxineThe serum concentration of Perphenazine can be increased when it is combined with Sulfadoxine.Approved
SulfamethoxazoleThe metabolism of Perphenazine can be decreased when combined with Sulfamethoxazole.Approved
SulfametopyrazineThe serum concentration of Perphenazine can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
SulfisoxazoleThe metabolism of Perphenazine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Perphenazine is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Perphenazine.Approved, Investigational
SuvorexantPerphenazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
tafenoquineThe serum concentration of Perphenazine can be increased when it is combined with tafenoquine.Investigational
TamoxifenThe metabolism of Perphenazine can be decreased when combined with Tamoxifen.Approved
TandospironeThe risk or severity of adverse effects can be increased when Perphenazine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Perphenazine is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Perphenazine.Approved
TelaprevirThe metabolism of Perphenazine can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Perphenazine can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Perphenazine.Approved
TenofovirThe metabolism of Perphenazine can be decreased when combined with Tenofovir.Approved, Investigational
TerbinafineThe metabolism of Perphenazine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe serum concentration of Perphenazine can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Perphenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Perphenazine is combined with Tetrodotoxin.Investigational
ThalidomidePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Perphenazine can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Perphenazine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Perphenazine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Perphenazine.Approved
ThiotepaThe metabolism of Perphenazine can be decreased when combined with Thiotepa.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Perphenazine is combined with Tiapride.Investigational
TicagrelorThe metabolism of Perphenazine can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Perphenazine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Tiletamine.Vet Approved
TimololPerphenazine may increase the hypotensive activities of Timolol.Approved
TipranavirThe metabolism of Perphenazine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Perphenazine.Approved
TocilizumabThe serum concentration of Perphenazine can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Perphenazine can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Perphenazine is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Perphenazine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Perphenazine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Perphenazine can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Triazolam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Perphenazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Perphenazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Perphenazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Perphenazine is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Perphenazine.Approved, Investigational
ValsartanThe metabolism of Perphenazine can be decreased when combined with Valsartan.Approved, Investigational
VemurafenibThe serum concentration of Perphenazine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Perphenazine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Perphenazine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Perphenazine is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Vilazodone.Approved
VoriconazoleThe metabolism of Perphenazine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Xylazine.Vet Approved
ZafirlukastThe metabolism of Perphenazine can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Perphenazine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Perphenazine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Perphenazine.Approved, Investigational
ZolpidemPerphenazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Perphenazine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Perphenazine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.
  • Take with food.
References
Synthesis Reference

DrugSyn.org

US2860138
General ReferencesNot Available
External Links
ATC CodesN05AB03
AHFS Codes
  • 28:16.08.24
PDB EntriesNot Available
FDA labelDownload (360 KB)
MSDSDownload (74.9 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9476
Blood Brain Barrier+0.9683
Caco-2 permeable-0.5126
P-glycoprotein substrateSubstrate0.7862
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.7689
Renal organic cation transporterInhibitor0.5807
CYP450 2C9 substrateNon-substrate0.7442
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.6813
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.9278
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9089
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7548
Ames testNon AMES toxic0.8093
CarcinogenicityNon-carcinogens0.8836
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.0725 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7745
hERG inhibition (predictor II)Inhibitor0.7066
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pharmaceutical assoc inc
  • Schering corp sub schering plough corp
  • Ivax pharmaceuticals inc
  • Sandoz inc
  • Vintage pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
TabletOral16 mg
TabletOral2 mg
TabletOral4 mg
TabletOral8 mg
TabletOral8 mg/1
Tablet, film coatedOral16 mg/1
Tablet, film coatedOral2 mg/1
Tablet, film coatedOral4 mg/1
Tablet, film coatedOral8 mg/1
Tablet, sugar coatedOral2 mg/1
Tablet, sugar coatedOral8 mg/1
TabletOral
Tablet, film coatedOral
LiquidOral3.2 mg
LiquidOral16 mg
SolutionIntramuscular; Intravenous5 mg
SyrupOral2 mg
Prices
Unit descriptionCostUnit
Perphenazine 16 mg tablet1.73USD tablet
Perphenazine 8 mg tablet1.28USD tablet
Perphenazine 4 mg tablet1.05USD tablet
Perphenazine 2 mg tablet0.77USD tablet
Apo-Perphenazine 16 mg Tablet0.13USD tablet
Apo-Perphenazine 8 mg Tablet0.09USD tablet
Apo-Perphenazine 4 mg Tablet0.08USD tablet
Apo-Perphenazine 2 mg Tablet0.07USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point97 °CPhysProp
boiling point278-281 °C at 1.00E+00 mm HgPhysProp
water solubility28.3 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.20HANSCH,C ET AL. (1995)
logS-4.16ADME Research, USCD
pKa7.94SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0237 mg/mLALOGPS
logP4.15ALOGPS
logP3.69ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)15.59ChemAxon
pKa (Strongest Basic)8.21ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area29.95 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity116.1 m3·mol-1ChemAxon
Polarizability44.77 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.95 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0002-4591100000-97d36958b3e0fe519db6View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazines
Sub ClassPhenothiazines
Direct ParentPhenothiazines
Alternative Parents
Substituents
  • Phenothiazine
  • Alkyldiarylamine
  • Diarylthioether
  • N-alkylpiperazine
  • Chlorobenzene
  • Benzenoid
  • Piperazine
  • 1,4-diazinane
  • Aryl halide
  • Aryl chloride
  • Para-thiazine
  • Tertiary aliphatic amine
  • Tertiary amine
  • 1,2-aminoalcohol
  • Azacycle
  • Thioether
  • Alkanolamine
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
  2. Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I: Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand. 1993 Dec;88(6):395-402. [PubMed:7508675 ]
  3. Qin ZH, Weiss B: Dopamine receptor blockade increases dopamine D2 receptor and glutamic acid decarboxylase mRNAs in mouse substantia nigra. Eur J Pharmacol. 1994 Sep 15;269(1):25-33. [PubMed:7828655 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  5. Talvik M, Nordstrom AL, Larsen NE, Jucaite A, Cervenka S, Halldin C, Farde L: A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration. Psychopharmacology (Berl). 2004 Sep;175(2):148-53. Epub 2004 Mar 6. [PubMed:15007534 ]
  6. Farde L, Wiesel FA, Nordstrom AL, Sedvall G: D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology (Berl). 1989;99 Suppl:S28-31. [PubMed:2573104 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Dolzan V, Plesnicar BK, Serretti A, Mandelli L, Zalar B, Koprivsek J, Breskvar K: Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment. Am J Med Genet B Neuropsychiatr Genet. 2007 Sep 5;144B(6):809-15. [PubMed:17455212 ]
  2. Farde L, Wiesel FA, Nordstrom AL, Sedvall G: D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology (Berl). 1989;99 Suppl:S28-31. [PubMed:2573104 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Titin binding
Specific Function:
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number of protein kinases and phosphatases. Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis.
Gene Name:
CALM1
Uniprot ID:
P62158
Molecular Weight:
16837.47 Da
References
  1. Mongin AA, Cai Z, Kimelberg HK: Volume-dependent taurine release from cultured astrocytes requires permissive [Ca(2+)](i) and calmodulin. Am J Physiol. 1999 Oct;277(4 Pt 1):C823-32. [PubMed:10516112 ]
  2. Kawai M, Nakashima A, Ueno M, Ushimaru T, Aiba K, Doi H, Uritani M: Fission yeast tor1 functions in response to various stresses including nitrogen starvation, high osmolarity, and high temperature. Curr Genet. 2001 May;39(3):166-74. [PubMed:11409178 ]
  3. Edlind T, Smith L, Henry K, Katiyar S, Nickels J: Antifungal activity in Saccharomyces cerevisiae is modulated by calcium signalling. Mol Microbiol. 2002 Oct;46(1):257-68. [PubMed:12366848 ]
  4. Natochin YuV, Shakhmatova EI, Bakos P: Water and sodium transport: effects of calcium channel blocker and calmodulin antagonists on the apical and basolateral membranes of amphibian epithelia. Gen Physiol Biophys. 1987 Feb;6(1):35-44. [PubMed:2885243 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Otani K, Aoshima T: Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit. 2000 Feb;22(1):118-21. [PubMed:10688273 ]
  2. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  3. Linnet K, Wiborg O: Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism. Clin Pharmacol Ther. 1996 Jul;60(1):41-7. [PubMed:8689810 ]
  4. Ozdemir V, Naranjo CA, Herrmann N, Reed K, Sellers EM, Kalow W: Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. Clin Pharmacol Ther. 1997 Sep;62(3):334-47. [PubMed:9333110 ]
  5. Hamelin BA, Bouayad A, Drolet B, Gravel A, Turgeon J: In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists. Drug Metab Dispos. 1998 Jun;26(6):536-9. [PubMed:9616188 ]
  6. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23